Adjuvant treatment after resection of biliary-tract cancer: yes or no?

  • Eveline Boucher | boucher@rennes.fnclcc.fr Centre Eugène Marquis, Oncologie Médicale, Rennes, France.
  • Marc Pracht Centre Eugène Marquis, Oncologie Médicale, Rennes, France.
  • Catherine Le Roux Centre Eugène Marquis, Oncologie Médicale, Rennes, France.
  • Karim Boudjema Département de Chirurgie viscérale, Centre Hospitalier Universitaire, Rennes, France.
  • Jean-Luc Raoul Centre Eugène Marquis, Oncologie Médicale, Rennes, France.

Abstract

Biliary-tract cancers are rare tumors and carry poor prognosis despite some aggressive surgical approach. The benefit of adjuvant treatment is under debate, and except one there is no phase III trial available. However, it appears that, in a large proportion, adjuvant therapy is proposed to patient. It could be chemotherapy or radiotherapy alone or both. Many publications are available on this topic. These are sometimes phase II studies, but mostly retrospective data about the experience of one center. All these studies have got many bias and the results must be interpreted with caution, even if patients could get some benefit of adjuvant therapy in case of adverse prognostic factors as positive resection margin and/or nodal involvement. In this review, we sum up the different therapies used as adjuvant treatment for biliary-tract cancer, and then we have studied what is done in clinical practice in order to propose a phase III clinical trial in this setting.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-05
Info
Issue
Section
Reviews
Keywords:
Adjuvant treatment - Surgery - Biliary-tract cancer
Statistics
  • Abstract views: 1291

  • FULL TEXT: 169
How to Cite
Boucher, E., Pracht, M., Le Roux, C., Boudjema, K., & Raoul, J.-L. (2011). Adjuvant treatment after resection of biliary-tract cancer: yes or no?. Oncology Reviews, 4(3), 167-170. https://doi.org/10.4081/oncol.2010.60